Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : John, Mike & Tom's Wild World of Stocks -- Ignore unavailable to you. Want to Upgrade?

To: wlheatmoon who wrote (194)	12/20/1999 3:47:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 2850

Regarding genomics--I was impressed with the degree of collaboration in assembling the sequence of Chromosome 22 (see Nature, 2 Dec 1999, page 489) At the end of the paper the list of contributers was given, around 150 names from at least a dozen research centers. Since I'm not half as bright as the average molecular biologist, I guess I should be careful about saying anything negative about these people--but the impression I have got on Venter is he is a bit of a showman. That does wonders for your shareprice, but maybe it is not in the best interest of the science. All the "Genome" stocks are pretty hot right now, I missed out on the meltup in Gene Logic and Hyseq and Curagen, I must be an idiot...but I do think there are still some awful good values out there. Incyte is always on my list, but I elected to go for Genset-- help diversify my biotech basket out of America a bit. I PMed one of your contributors on this thread, he thought it would be okay if posted here. Thanks for any thoughts you might have--if you have anything negative to say about genxy by all means speak up--I put my wife in this one and have a target in the mid 20s. --Mike